HomeSectors Biotechnology

Biotechnology

CSL Share Price at $140: What the 2026 Forecast Really Says

Mesoblast Investor & Research Update Signals Key April R&D Day

Immutep Stock Plunges as Lung Cancer Trial Ends: What Happened

Neuren Monitors EU Review of Acadia Drug Filing

Cochlear HY26 Financial Results Show Nexa Rollout Impact

Neuren Pharmaceuticals Welcomes Reauthorisation of US Priority Review Voucher Program

Neuren Pharmaceuticals Confirms Daybue Sales Outlook After ASX Aware Letter

Affordable £2.50 Drug Extends Lives of Prostate Cancer Patients

JPMorgan Healthcare Conference 2026 Breaks Ground On Pharma Frontiers

Aged Care Crisis Australia Deepens As Allman-Payne Blasts Health Officials Over System Failures

COLITCO LLP accepts no responsibility for any claim, loss or damage as a result of information provided or its accuracy. The information provided on this site is general in nature, not financial product advice, see a financial expert before making any investment decision. Your personal objectives, financial situation or needs have not been taken into consideration. There may be a conflict of interest present with commercial arrangements with companies and/or stock held. COLITCO LLP or an associate may receive a commission for funds raised.

↑

Biotechnology

Recent Posts

Categories

Disclaimer

Categories

Trending Posts